# IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

> **NCT06119685** · PHASE1,PHASE2 · RECRUITING · sponsor: **Indapta Therapeutics, INC.** · enrollment: 128 (estimated)

## Conditions studied

- NHL
- Multiple Myeloma
- Blood Cancer
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** IDP-023
- **DRUG:** Rituximab
- **DRUG:** Daratumumab
- **DRUG:** Interleukin-2
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna
- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT06119685
- **Lead sponsor:** Indapta Therapeutics, INC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2025-12-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06119685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06119685, "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06119685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*